Quick Answer
Elicio Therapeutics, Inc. reported Operating Income of -$37.71 million for fiscal year 2025.
Elicio Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$37.71M | +16.2% |
| 2024 | -$44.99M | -25.9% |
| 2023 | -$35.74M | -50.6% |
| 2022 | -$23.73M | +39.6% |
| 2021 | -$39.31M | +28.9% |
| 2020 | -$55.27M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.04M | +22.2% | +20.3% |
| June 30, 2025 | -$10.09M | +7.6% | +6.0% |
| March 31, 2025 | -$10.74M | -4.8% | -3.8% |
| September 30, 2024 | -$10.34M | +4.0% | +5.3% |
| June 30, 2024 | -$10.92M | -40.5% | -6.7% |
| March 31, 2024 | -$10.24M | -31.2% | +4.9% |
| September 30, 2023 | -$10.77M | -86.7% | -38.5% |
| June 30, 2023 | -$7.78M | -24.8% | +0.4% |
- Elicio Therapeutics, Inc. showed an increase of +16.2% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Elicio Therapeutics, Inc.’s operating income has grown by 31.8% (from -$55.27 million to -$37.71 million).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: